Biology Faculty Articles

Title

Telithromycin. Fresh from the Pipeline

Document Type

Article

Publication Date

9-1-2004

Publication Title

Nature Reviews Drug Discovery

ISSN

1474-1776

Abstract

In April 2004, telithromycin (Ketek; Aventis), the first of a new class of antibacterial drugs derived from macrolides, was approved by the US FDA for the treatment of several respiratory-tract infections. After a delay in its approval owing to a need to address potential safety issues, is it likely to now attain the blockbuster status that had originally been widely predicted?

This document is currently not available here.

Find in your library

Share

COinS